Morfina Basi (Morphine)

Morphine binds to μ‑opioid receptors in the brain, spinal cord and peripheral nervous system. This binding inhibits the release of excitatory neurotransmitters, reduces neuronal excitability, and alters the perception and emotional response to pain, resulting in analgesia.

The appropriate dose of Morfina Basi is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, route of administration, and individual health status. Dosage adjustments are made to achieve effective pain control while minimizing adverse effects.

Morphine is classified as Pregnancy Category C, meaning risk cannot be ruled out. It should be used only if the potential benefit justifies the potential fetal risk. Morphine is excreted in breast milk; breastfeeding mothers should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Morphine is considered the gold‑standard opioid for severe pain, offering a well‑characterized efficacy and safety profile. Compared with newer synthetic opioids, morphine has a longer history of clinical use, predictable pharmacokinetics, and is generally less expensive, though it may have a higher incidence of certain side effects such as constipation.

Morfina Basi should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and ensure that any reconstituted solutions are used within the time frame specified by the manufacturer.

Morfina Basi is supplied as an injectable formulation intended for epidural, intracerebroventricular or other parenteral routes. Administration is performed by qualified healthcare professionals under aseptic conditions, with dosing individualized to the patient’s clinical needs and monitored for efficacy and safety.

The most serious risks include respiratory depression, severe hypotension, and the potential for dependence or addiction with prolonged use. Patients should be closely monitored for signs of respiratory compromise, especially after dose escalations or when combined with other central nervous system depressants.

Morfina Basi is contraindicated in patients with known hypersensitivity to morphine or any component of the formulation, in those with severe respiratory depression, acute or severe bronchial asthma, and in individuals who have taken monoamine oxidase inhibitors within the past 14 days.